About Glucagonoma
Glucagonoma is a rare functional pancreatic neuroendocrine tumour arising from alpha cells that secrete excessive glucagon, producing a distinctive clinical syndrome dominated by necrolytic migratory erythema, a characteristic skin rash, alongside diabetes mellitus, hypoaminoacidaemia, weight loss, anaemia, and venous thrombosis. The rash, which migrates and heals centrally while expanding peripherally and frequently affects the perineum, lower abdomen, and extremities, is often the presenting feature that leads to diagnosis. More than 60–70% of glucagonomas are malignant at presentation, with hepatic metastases frequently present, rendering curative resection impossible in many patients.
Common Clinical Features
Clinical Trial Eligibility Tips
What to know before applying to Glucagonoma trials.
Fasting serum glucagon level above 500 pg/mL, combined with imaging evidence of a pancreatic mass and characteristic symptoms, is the standard diagnostic threshold used for trial enrolment.
Somatostatin receptor scintigraphy or 68Ga-DOTATATE PET scan demonstrating receptor positivity is required for trials of somatostatin analogues or peptide receptor radionuclide therapy (PRRT).
Thromboprophylaxis and nutritional status (albumin, amino acid levels) are assessed at baseline screening; patients with active deep vein thrombosis or severe malnutrition may need stabilisation before enrolment.
Patient Resources
Find recruiting Glucagonoma trials
Search 500,000+ studies from ClinicalTrials.gov, filtered for Glucagonoma. Updated daily.